Price
CHART BY
Frequently asked questions
What is Bio Rad's market capitalization?
The market capitalization of Bio Rad is $9.17B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Bio Rad?
Bio Rad's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$27.33. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Bio Rad's stock?
Currently, 8 analysts cover Bio Rad's stock, with a consensus target price of $399.33. Analyst ratings provide insights into the stock's expected performance.
What is Bio Rad's revenue over the trailing twelve months?
Over the trailing twelve months, Bio Rad reported a revenue of $2.58B.
What is the EBITDA for Bio Rad?
Bio Rad's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $540.96M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Bio Rad?
Bio Rad has a free cash flow of $246.55M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Bio Rad have, and what sector and industry does it belong to?
Bio Rad employs approximately 8,030 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Bio Rad's shares?
The free float of Bio Rad is 19.17M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $9.17B
- EPS (TTM)
- -$27.33
- Free Float
- 19.17M
- Revenue (TTM)
- $2.58B
- EBITDA (TTM)
- $540.96M
- Free Cashflow (TTM)
- $246.55M
Pricing
- 52W span
- $263.50$380.00
Analyst Ratings
The price target is $399.33 and the stock is covered by 8 analysts.
Buy
5
Hold
3
Sell
0
Information
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
- Employees
- 8,030
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- US0905722072
- Primary Ticker
- BIO